These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 27488521)

  • 1. Inducing Differentiation of Premalignant Hepatic Cells as a Novel Therapeutic Strategy in Hepatocarcinoma.
    Wolf B; Krieg K; Falk C; Breuhahn K; Keppeler H; Biedermann T; Schmid E; Warmann S; Fuchs J; Vetter S; Thiele D; Nieser M; Avci-Adali M; Skokowa Y; Schöls L; Hauser S; Ringelhan M; Yevsa T; Heikenwalder M; Kossatz-Boehlert U
    Cancer Res; 2016 Sep; 76(18):5550-61. PubMed ID: 27488521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways.
    Li H; Zhang J; Lee MJ; Yu GR; Han X; Kim DG
    Oncotarget; 2017 Mar; 8(11):18129-18144. PubMed ID: 28184024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT.
    Noh JH; Bae HJ; Eun JW; Shen Q; Park SJ; Kim HS; Nam B; Shin WC; Lee EK; Lee K; Jang JJ; Park WS; Lee JY; Nam SW
    Cancer Res; 2014 Mar; 74(6):1728-38. PubMed ID: 24448241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells.
    Umemura A; He F; Taniguchi K; Nakagawa H; Yamachika S; Font-Burgada J; Zhong Z; Subramaniam S; Raghunandan S; Duran A; Linares JF; Reina-Campos M; Umemura S; Valasek MA; Seki E; Yamaguchi K; Koike K; Itoh Y; Diaz-Meco MT; Moscat J; Karin M
    Cancer Cell; 2016 Jun; 29(6):935-948. PubMed ID: 27211490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells.
    Roberts JL; He B; Erickson A; Moreau R
    Biochim Biophys Acta; 2016 Mar; 1861(3):166-76. PubMed ID: 26680362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
    Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
    J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma.
    Jariwala N; Rajasekaran D; Mendoza RG; Shen XN; Siddiq A; Akiel MA; Robertson CL; Subler MA; Windle JJ; Fisher PB; Sanyal AJ; Sarkar D
    Cancer Res; 2017 Jun; 77(12):3306-3316. PubMed ID: 28428278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells.
    Wan ZY; Tian JS; Tan HW; Chow AL; Sim AY; Ban KH; Long YC
    Hepatology; 2016 Oct; 64(4):1289-301. PubMed ID: 27178107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tumor-initiating cells in a canine hepatocellular carcinoma cell line.
    Michishita M; Ezaki S; Ogihara K; Naya Y; Azakami D; Nakagawa T; Sasaki N; Arai T; Shida T; Takahashi K
    Res Vet Sci; 2014 Apr; 96(2):315-22. PubMed ID: 24534130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
    Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
    Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
    Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
    Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of BNIP3 mediated by ERK/HIF-1α pathway induces autophagy and contributes to anoikis resistance of hepatocellular carcinoma cells.
    Sun L; Li T; Wei Q; Zhang Y; Jia X; Wan Z; Han L
    Future Oncol; 2014 Jun; 10(8):1387-98. PubMed ID: 25052749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a novel system for the culture and expansion of hepatic stem-like cancer cells.
    Li J; Yu Y; Wang J; Yan Z; Liu H; Wang Y; Ding M; Cui L; Wu M; Jiang X; Qian Q
    Cancer Lett; 2015 May; 360(2):177-86. PubMed ID: 25676692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of β-catenin signaling.
    Lei ZJ; Wang J; Xiao HL; Guo Y; Wang T; Li Q; Liu L; Luo X; Fan LL; Lin L; Mao CY; Wang SN; Wei YL; Lan CH; Jiang J; Yang XJ; Liu PD; Chen DF; Wang B
    Oncogene; 2015 Jun; 34(24):3188-98. PubMed ID: 25893304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation inhibition and differentiation induction of hepatic cancer stem cells by knockdown of BC047440: a potential therapeutic target of stem cell treatment for hepatocellular carcinoma.
    You N; Zheng L; Liu W; Zhong X; Wang W; Li J
    Oncol Rep; 2014 Apr; 31(4):1911-20. PubMed ID: 24573111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.
    Shi Y; Daniels-Wells TR; Frost P; Lee J; Finn RS; Bardeleben C; Penichet ML; Jung ME; Gera J; Lichtenstein A
    Cancer Res; 2016 Oct; 76(19):5822-5831. PubMed ID: 27530328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma.
    Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T
    Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.